Today: 3 February 2026
Subscribe
Browse Category

NYSE:TEVA News 23 December 2025 - 12 January 2026

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

New York, Jan 12, 2026, 10:13 ET — Regular session Teva Pharmaceutical Industries’ U.S.-listed shares jumped roughly 4% to $33.29 in Monday morning trading. The boost came after the drugmaker unveiled new funding for an experimental vitiligo treatment and offered a glimpse of its year-end outlook. This move is crucial as Teva aims to prove to investors that its growth…
12 January 2026
·····
Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Stock News on Dec. 24, 2025: TEVA Rallies on S&P Credit Upgrade, $40 Price Target Hike, and Fresh Pipeline Catalysts

Teva Pharmaceutical Industries Limited (NYSE: TEVA; TASE: TEVA) stock is finishing 2025 with unusual momentum for a company long labeled “just a generics maker.” On Dec. 24, 2025, TEVA is trading around the $31–$32 range after a sharp run-up over the past several weeks, with holiday-thinned markets now digesting a cluster of developments that bulls say strengthen Teva’s “pivot to…
24 December 2025
····
Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries (TEVA) Stock Hits Fresh Highs as S&P Upgrades Credit Rating and Analysts Lift Targets to $40

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is back in the market spotlight on December 23, 2025, with its stock hovering near the top of its 52-week range as a pair of momentum-friendly headlines land at once: a credit rating upgrade from S&P Global Ratings and a fresh bull-case valuation reset from Piper Sandler. Teva shares traded around $31.21, with the…
23 December 2025
···

Stock Market Today

  • 3M Stock Analysis 2026: Earnings, Performance, and Price Targets
    February 2, 2026, 6:41 PM EST. Shares of industrial giant 3M Company (MMM) have notably lagged the broader market over the past year, gaining only slightly compared to the S&P 500's 14.3% surge. Year-to-date, MMM is down 4.4%, trailing behind key benchmarks including the State Street Industrial Select Sector SPDR ETF's 6.6% rise. Despite better-than-expected Q4 earnings-with revenue of $6.1 billion and adjusted EPS of $1.83-MMM's shares tumbled 7% amid geopolitical tensions impacting investor sentiment. Analysts project a 6.3% EPS growth for fiscal 2026, estimating $8.57 per share. Consensus across 16 analysts leans towards a 'Moderate Buy' rating, though slightly less bullish than last month. Price targets vary widely, with a mean target of $179.33 and a high of $200, indicating significant potential upside from current levels.
Go toTop